News articles about Moleculin Biotech (NASDAQ:MBRX) have trended somewhat positive on Monday, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Moleculin Biotech earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.4456961277636 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Separately, ValuEngine upgraded Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

Moleculin Biotech (MBRX) traded down 3.63% during midday trading on Monday, hitting $2.39. The company had a trading volume of 242,998 shares. The company’s market capitalization is $48.42 million. Moleculin Biotech has a 52 week low of $0.71 and a 52 week high of $6.34. The stock has a 50 day moving average price of $2.52 and a 200 day moving average price of $1.45.

Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings data on Monday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter. Equities analysts forecast that Moleculin Biotech will post ($0.34) earnings per share for the current fiscal year.

In related news, major shareholder Waldemar Priebe sold 100,000 shares of the stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $1.70, for a total value of $170,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 20.80% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Moleculin Biotech (MBRX) Given Daily Media Impact Rating of 0.03” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Insider Buying and Selling by Quarter for Moleculin Biotech (NASDAQ:MBRX)

Receive News & Ratings for Moleculin Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech Inc. and related companies with's FREE daily email newsletter.